Biocracked
Conceptual metaphor: a cube of pale yellow wax, the size of a fist, stands for abdominal fat. A clear glass syringe is inserted into its top face, and one small, smooth, glossy crater has melted around the needle. The rest of the cube stays sharp-edged and untouched, which shows the effect is local, not systemic. Fine droplets of melted wax bead at the crater's rim. The syringe plunger has a small electric green tip.

The camera is at a low three-quarter angle with a shallow depth of field, focused on the needle entry point. The cube sits on a seamless saturated teal backdrop and a matching glossy teal surface, with a faint reflection beneath it. Soft, directional studio light comes from the upper left, giving the wax a translucent glow and crisp highlights on the glass. Shadows are neutral grey-teal, not blue-black.

The mood is precise, curious and slightly skeptical, with a clean, modern, photorealistic look.
Research

Menene CBL‑514? Shin yana ƙone kitse?

Dr. Synapse · · 6 min read

Menene CBL‑514? Shin yana ƙone kitse?

Siffa: CBL‑514 an kiransa da “allurar narkar da mai”, amma ba allura ce da ke ƙone kitse ba, ba ƙara ba, kuma ba GLP‑1 ba. Shi maganin ƙwaya ne da Caliway Biopharmaceuticals ke haɓaka, wanda aka tsara don haifar da apoptosis a cikin ƙwayoyin kitse a wurin da aka yi allura. A gwajin mataki na 2 da aka gudanar a 2025, adadin ƙashin ciki ya ragu da kusan ‑216 mL a cikin makonni 8 idan aka kwatanta da placebo, yayin da nauyin jiki bai canza ba (≈+0.02 kg). Saboda haka, sakamakon ya nuna rage kitse a ƙarƙashin fata, ba ƙone kitse gaba ɗaya ba. Saboda yawan fita daga gwaji, ƙira ɗaya‑blind, da shiga mai tallafa, dole ne a yi nazari da hankali.

CBL‑514 (wani lokaci ana rubuta shi “CL‑514”) a yanar gizo

Ana yawan ganin CBL‑514 a matsayin “allurar narkar da mai”. Wannan bayanin na da wani ɓangare na gaskiya, amma “ƙone mai” ba daidai ba ne. CBL‑514 maganin ƙwaya ne da ke ƙoƙarin haifar da apoptosis a cikin ƙwayoyin kitse a wurin da aka yi allura. Ba maganin ƙone kitse na metabolic ba, ba GLP‑1 ba, kuma ba ƙari ba ne.

Abin da takardun da aka wallafa suka nuna

Menene CBL‑514, kuma menene ba shi ba

Sunan da ya dace shine CBL‑514. “CL‑514” kuskure ne da ya bayyana a wasu takardu, kuma shine kawai lokacin da ake gani a wannan rubutu.

CBL‑514:

  • Maganin ƙwaya da ake bincike wanda za a iya allura.
  • Ana ba da shi a matsayin allura a ƙarƙashin fata (subcutaneous) a wurin da ake maganin. A gwajin mataki na 2, wannan wurin ya kasance ƙashin ciki.
  • Masu gudanar da binciken ne ke ba da shi a cikin gwaji na klinik.

CBL‑514 ba:

  • Ƙari ko maganin da ake sha.
  • Samfurin da aka amince da shi ga masu amfani.
  • An amince da shi ta FDA; takardar mataki na 2 da aka wallafa ba ta nuna hakan ba.

Kayan da FDA ta amince da shi don rage kitse shine ATX‑101 (deoxycholic acid), wanda aka sani da Kybella. An amince da shi ne kawai don ƙashin karkashin ƙafafu (submental fat). A yanzu CBL‑514 na ci gaba da bincike don manyan wurare kamar ƙashin ciki, amma har yanzu yana cikin matakin gwaji.

Yadda ake tunanin aikin maganin

Takardar mataki na 2 ta bayyana CBL‑514 a matsayin “maganin ƙwaya da ke haifar da lipolysis wanda ke ƙarfafa apoptosis a cikin adipocytes kuma rage ƙashin ƙasa a cikin binciken ba na mutum ba”. Waɗannan ikirarin ba na mutum ba su dogara ne a kan rahotanni na sirri daga Caliway da takardar Phase 2a da ta fito (Goodman et al., 2022). A cewar wannan bincike na farko, CBL‑514 yana toshe kinase DYRK1b da ke taimakawa rayuwar sel, sannan yana ƙara samuwar masu kashe sel kamar caspase‑3 da Bax/Bcl‑2. Wannan yana haifar da apoptosis ga adipocytes a cikin gwaje‑gwaje na in‑vitro da in‑vivo, dangane da ƙimar magani. A sauƙaƙe, manufar ita ce tura ƙwayoyin kitse a wurin da aka yi allura su mutu ta hanyar apoptosis, ba don ƙara metabolic rate ko ƙone kalori gaba ɗaya ba. Dandamalin maganin ba a bayyana shi a takardun ba, don haka duk wani ikirari game da cikakken sunan, mai karɓa, ko sinadarai na gaba ɗaya shi ne hasashe ne kawai.

Shaida daga ɗan adam: Gwajin Phase 2 na 2025

Babban bayanin ɗan adam ya zo daga gwaji da aka tsara single‑blind, placebo‑controlled, Phase 2. An gudanar da shi a cibiyoyi biyar a Amurka da Australia tsakanin Fabrairu 2022 zuwa Maris 2023, kuma an wallafa a Aesthetic Surgery Journal a 2025 (matakin shaida 2).

  • Girman: Mutane 130 aka duba, 81 aka shiga, 76 aka raba (50 CBL‑514, 26 placebo), 75 aka magance.
  • Ƙungiyoyi: manya masu shekaru 18‑64 da BMI tsakanin 18.5‑35 kg/m². A ƙungiyar CBL‑514, kashi 94 % mata ne.
  • Magani: har zuwa allura huɗu a kowane mako 4. Kowanne magani ya ƙunshi allura 25‑50 na 2.4 mL a 2 mg/cm², har zuwa 600 mg a kowanne magani. Placebo shine normal saline.
  • Ma’auni: kauri na kitse ta hanyar ultrasound a maki huɗu, an juya zuwa girma a fadin wurin magani na 300 cm².

Blindness wata ƙuntatawa ce. Ɗan takara kawai aka ɓoye. Masu bincike, ma’aikatan cibiyar, da mai tallafa sun kasance a buɗe. Caliway ta kuma shiga cikin tsara gwaji, nazarin bayanai, rubuta takarda, da yanke shawarar wallafa.

To, shin yana ƙone kitse?

Ya rage kitse a ƙasa idan aka kwatanta da placebo. Ba ya haifar da ƙone kitse gaba ɗaya ko raguwar nauyi.

Game da rage kitse a ƙasa, gwajin ya cika babban manufarsa na rasa aƙalla 150 mL na girman kitse. A binciken intention‑to‑treat (ITT):

  • Mako 4 bayan ƙarshe magani: kashi 63.9 % na mahalarta CBL‑514 (23/36) suka kai aƙalla 150 mL, yayin da kashi 17.4 % na placebo (4/23) suka kai, P < .001.
  • Mako 8: 69.6 % (16/23) vs 0.0 % (0/16), P < .001.
  • Matsakaicin rasa: bambanci na least‑squares mean ya kasance ‑206.62 mL a mako 4 da ‑216.28 mL a mako 8.
  • Mafi girma a rasa: fiye da 750 mL a wani mahalarta ɗaya.

A kan nauyin jiki, canjin matsakaici a ƙungiyar CBL‑514 ya kasance +0.45 kg a mako 4 kuma +0.02 kg a mako 8. Group na placebo ya canza da ‑0.76 kg da ‑0.26 kg. Takardar ba ta nuna canjin muhimmanci a matsakaicin nauyi ko BMI ba. Hakanan ta ce wasu mahalarta da suka ƙara fiye da 1 kg har yanzu sun nuna ragin kitse a ƙasa, duk da ba a nuna wannan bayanin ba. Wannan yanayi shine abin da za a zata daga hanya ta kashe ƙwayoyin kitse a ƙasa, ba daga ƙone kitse na metabolism ba.

Gargadi kafin a yi farin ciki

Wannan lambobi suna da kwarin gwiwa ga wani gwaji da yake farawa, amma takardar na da manyan ƙuntatawa.

  • Yawan fita: Daga mahalarta 75 da aka magance, 38 suka kammala gwaji, 37 ba su kammala ba, wato 49.3 % ba su kammala. Dalilan sun haɗa da rasa hanyar bin, janye, rashin daidaiton nauyi, matsalolin jadawalin, da abubuwan rashin lafiya (mutane 4).
  • Raguwar ƙima: Kashi na ITT da aka ambata ya dogara ne akan mahalarta 36 sannan 23 na CBL‑514 saboda rashin bin diddigin.
  • Ƙungiyar per‑protocol ƙanana: Yawan PP mutane 30 ne kawai. Tasirin da ya fi girma (matsakaicin ‑314.70 mL a mako 4 a ƙungiyar CBL‑514) ya fito ne daga mutanen da suka ci gaba da bin hanya da kuma daidaiton nauyi, don haka yana ba da kyakkyawan hangen nesa ga maganin.
  • Tsarin bincike mai ƙarfi: Ba a yi amfani da ƙididdigar ƙarfi ta hanyar da ta dace ba, kuma ba a daidaita sakamakon don gwaje‑gwajen da yawa ba.
  • Populashen kankane: Mahalarta mafi yawa mata ne kuma farar fata.
  • Volume da ultrasound ya ƙirƙira: An ƙirƙiri girma ta hanyar tsari na cuboid daga kaurin ultrasound, ba a auna shi kai tsaye ba.

Masu rubutu suna kwatanta sakamakon da gwaje‑gwajen cryolipolysis kuma suna cewa alamar “ta fi girma”, kuma suna kwatanta sakamako da liposuction. Wadannan ra'ayoyi ne na masu rubutu. Hanyoyin auna daban‑daban ne, kuma babu gwajin kai‑tsaye da CoolSculpting ko liposuction. Zaton marasa laushi na fata da aka gani a hotunan bayan magani ya fito ne daga hoton, ba daga ma'aunin laushi na zahiri ba.

An tantance lafiyar ta hanyar abubuwan da suka faru, gwajin jini, sigogin rayuwa, ECG, duba jiki, da martani a wurin allura. Masu karatu da ke damuwa da tsaron jiki ya kamata su karanta sashin lafiya cikakken takarda maimakon dogaro da taƙaitaccen bayani.

Kammalawa ga masu son biohacking

CBL‑514 yana da ban sha'awa a fannin biotechnologia: maganin ƙwaya ne da ke nufin sanya ƙwayoyin kitse a wurin da aka yi allura su mutu ta hanyar apoptosis. Bayanai na Phase 2 suna nuna zai iya rage girman kitse a ƙashin ciki fiye da saline, ba tare da wani babban canjin nauyi ba. Wannan shine alamar maganin da aka keɓe don gyaran jiki, ba ƙone kitse ba.

Har yanzu yana bukatar ƙarin gwaje‑gwaje, domin ba a amince da shi ba, kuma ba ƙari ba ne. Ba wani abu ne da za a sayi ko a yi allura da kai ba. Duk wani abu da ake sayarwa a yanar gizo da wannan suna ba tare da shiga gwaji ba ba a san shi ba, kuma tsarin kwayar ba a bayyana ba. Za a buƙaci manyan gwaje‑gwaje masu sa ido, waɗanda suka fi blind, kuma masu tsawon lokaci don tabbatar da ko sakamakon farko na da tasiri.

Majiyar: Gold M, Schlessinger J, Goodman GJ, et al. Efficacy and Safety of CBL‑514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single‑Blind, Placebo‑Controlled Phase II Study. Aesthet Surg J. 2025;45(6):611‑620. PMC12080885 | PMID 40037659 | doi.org/10.1093/asj/sjaf032

Original study

Read the original research on pmc.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach 1, macro science, with Palette D, bold color field.

Extreme close-up microscopy-style photograph of a cluster of adipocytes (fat cells). Each is a translucent, pale yellow sphere with a thin membrane, and a few are shrunken and crinkled to suggest apoptosis. The cells sit against a saturated magenta backdrop. The camera is slightly above, at a shallow 30-degree angle, with a very shallow depth of field so the foreground cells are razor sharp and the rest melts into soft bokeh. Hard, clean side light from the left makes the membranes glisten and casts crisp magenta-tinted shadows. One tiny electric green fluorescent speck glows inside a single collapsing cell as a subtle accent. The mood is precise, clinical and curious, with a bold editorial feel. There is no text and no blue cast.
research

Allurar CBL-514 Lipolysis: Binciken Mataki na 2

BY DR. SYNAPSE ·

CBL‑514 wani allura ne da ake bincike don haifar da apoptosis na sel ɗin kitse (adipocytes) a cikin ciki. A gwajin mataki na 2 da aka gudanar a 2025 tare da mahalarta 76 da aka raba ta bazuwar, an samu raguwar ƙimar kitse da aka auna ta ultrasound idan aka kwatanta da saline, yayin da matsakaicin nauyin jiki ya tsaya ba tare da canji ba. Ƙididdigar ta gabatar da ƙirar gwajin, ƙimar 2 mg/cm², cikakkun bayanan tasiri da ƙananan lambobi, da hanyar DYRK1b/caspase da kamfanin ya ba da rahoto. An kuma bayyana iyakokin: ƙirar single‑blind, haɗin gwiwar mai tallafa, kusan 49 % rashin kammalawa, gajeren lokaci na bibiyar, da yawan samfurin mata.

Approach 2, lab in action, with palette D, bold color field.

Straight-on, slightly elevated close shot of a gloved hand in a pale nitrile glove holding a glass syringe with a fine needle. The syringe is filled with clear liquid and sits over a row of small glass vials in a matte white rack. The whole scene sits against a saturated tomato-red seamless backdrop. Soft, even studio light gives crisp highlights along the syringe barrel and the vial glass, plus gentle warm-red reflections on the surfaces. A thin electric green (#00e676) cap on one vial is the only small accent. The dosing markings on the syringe are blurred and unreadable. Shallow depth of field blurs the back vials into soft shapes. The mood is precise, clinical and investigational, with high contrast and a measured, careful feel. No text, no labels, no logos.
research

Matsakaicin Magani na CBL‑514 – Menene Kimiyyar Sa?

BY DR. SYNAPSE ·

Gwaje‑gwajen CBL‑514 su ne gwaje‑gwajen allura da ke binciken tasirin wannan magani, inda adadin 600 mg ke nufin iyakar adadin da ake amfani da shi a kowanne magani a gwaji, ba adadin da za a ci ba. Wannan makala ta bi takaitaccen binciken Phase 2a don tantance ƙimomi (1.2, 1.6, 2.0 mg/cm² a kan 150 cm², n=43, buɗe‑label) kuma ta fayyace asalin adadin 24.96 % da aka ambata. Sannan ta duba Phase 2 da aka gudanar da placebo, inda aka ci gaba da ƙimar 2.0 mg/cm² amma an ninka yanki zuwa 300 cm² tare da iyaka ta 600 mg. Za ku ga dalilin da yasa adadin mg ba za a iya kwatanta su tsakanin gwaje‑gwajen ba, abin da aka rubuta game da tsaro, da kuma dalilin da ya sanya har yanzu ba a amince da shi ba ko ba da shawara ba.

Approach: the human outcome. Palette: bold color field.

A close, slightly high three-quarter view of a bare abdomen, cropped at the ribs and hips with no face. A hand in an electric green (#00e676) nitrile glove pinches a fold of belly skin and holds a slim syringe with the needle just about to enter. Faint yellow-purple bruising near the injection site hints at the side effects. The torso fills the frame against a flat, saturated teal backdrop that contrasts with the warm skin tones. Soft, even studio light from the left gives gentle shadows and visible skin texture, with fine pores and small hairs. The syringe tip is in sharp focus and the background falls away. No text or markings anywhere. The mood is clinical, unsentimental and skeptical.
research

Shin CBL‑514 na ƙona mai ainihi? Ga abin da muka sani

BY HELIX WARD ·

Binciken mataki na biyu da aka gudanar a 2025 kan CBL‑514 bai nufin rage nauyin jiki ba; an duba ko alluran da aka yi a ƙirji za su iya rage aƙalla mililita 150 na kitse a ƙarƙashin fata ta hanyar ultrasound. Bayan makonni 8, kashi 69.6 % (16/23) na masu karɓar CBL‑514 sun cimma wannan ragi, yayin da babu ɗaya a rukunin placebo. Duk da haka, matsakaicin nauyin jiki bai ragu ba (ƙara 0.02 kg) kuma kusan rabi na mahalarta ba su kammala binciken ba. Martani a wurin allura ya kasance gama‑gari, ciki har da ƙura a fata a 71.4 % da zafi mai tsanani a 18.4 %. Wannan shine abin da binciken ya nuna da abin da bai nuna ba.

**Approach 1 (macro science), Palette D (bold color field).**

Extreme close-up microscopy-style photograph of a cluster of fat cells (adipocytes), rendered as translucent, pearly spheres with thin membranes and tiny lipid droplets inside. One cell in the center is visibly shrinking and blebbing, its membrane crinkled and fragmenting into small beads, the look of apoptosis. A few of the surrounding cells are intact and glossy. The cells sit against a saturated tomato-red backdrop, so the pale yellow-cream spheres stand out sharply. The camera looks straight down at shallow depth of field, with the focal plane on the dying cell and the edges softly blurred. Soft, diffuse top light gives gentle highlights and warm shadows, with no blue cast. One thin electric green fluorescent ring around the central cell's nucleus is the only green accent. The mood is analytical, precise and quietly skeptical.
research

Ta yaya CBL‑514 ke aiki? Ilimin kimiyya

BY DR. SYNAPSE ·

CBL‑514 ba a nuna shi a matsayin maganin narkewar ko kona kitse ba. Da'awar da ake yi ita ce yana hanawa kinase DYRK1b aiki sannan ya tilastawa ƙwayoyin kitse shiga apoptosis ta hanyar caspase‑3 da Bax/Bcl‑2. Hujjar wannan zaɓi ta samo asali ne daga rahotannin kamfanin da ba a wallafa ba a takardun Phase 2a da Phase 2, kuma ba a fayyace takamaiman tsarin sinadarin ba. Gwajin Phase 2 na 2025 ya auna girman kitse da ultrasound, hotuna, da aminci, ba tare da ƙarin bayanai kamar biopsi ko caspase ba. Wannan labarin na nuni da bambanci tsakanin tunanin sel da abin da aka auna a ɗan adam, ciki har da yawan mutuwar mahalarta da tsarin single‑blind.

This page is available in